Hepatitis B markers in men having high risk sexual practices in Mexico City. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Hepatitis B markers in men having high risk sexual practices in Mexico City.

Int Conf AIDS. 1996 Jul 7-12;11(1):130 (abstract no. Mo.C.1433). Unique Identifier : AIDSLINE MED/96921493
Juarez-Figueroa L; Uribe F; Conde C; Del Rio C; Hernandez M; National Institute for Public Health, Mexico. Fax: (5273) 175485.


Abstract: Objective: To estimate the prevalence and associated risk factors of Hepatitis B virus (HBV) serological markers, "s" antigen HBsAg) and antibodies for "c" antigen (anti-HBc) in men with high risk sexual practices. Methods: Between January, 1992 and February, 1993, we interviewed and obtained a blood sample from 1378 men who voluntarily seeked HIV testing at one information center for the Control and Prevention of AIDS, in Mexico City(CONASIDA). The sample selected for this study represents a population with high risk practices which is self-selected as being at risk for acquiring HIV infection.All study participants responded to a standardized questionnaire designed to collect information about risk factors associated with sexually transmitted disease transmission, as well as other relevant factors related to the socio-economic and educational level of the participants. After filling out the questionnaire, the participants received counselling in relation to the HIV and hepatitis tests and about the risk factors identified in the questionnaire.In order to determine HBV carrier prevalence, HBsAg was detected. To determine the prevalence of individuals who had been exposed to the virus in the past, antibodies to `c' antigen anti-HBc) were detected. For syphilis, RPR test was done and confirmed with the FTA Abs test. Results of HIV antibody analysis were provided by CONASIDA. Laboratory and questionnaire results were data entered in DBase, and bivariate analysis and logistic regression multivariate analysis was performed. Results: We found that 1.8% of the population were HBsAg carriers. There was a large difference between the prevalences of HBsAg among HIV-negative individuals (0.8%) as compared to HIV-positive individuals (7.9%). Likewise, only 0.3% of men with exclusively female sexual partners were HBsAg carriers, as compared to 4.8% of men with exclusively masculine sexual partners.General anti-HBc prevalence in the study population was 15.4%. However, among men with exclusively female partners, we found 4.6% prevalence, while for men with exclusively male partners we found a prevalence of 30.4%.Logistic regression showed an association with age, sexual preference and being seropositive for HIV, T. pallidum Conclusions: In HIV-positive Mexican men, co-infection with the hepatitis B virus is quite common. The high prevalence of anti-HBc found among men with male sexual partners indicates the need to intensify safe sex education campaigns, as well as recommending vaccination among these groups.
Keywords: *Hepatitis B/EPIDEMIOLOGYKWDhepatitisb/epidemiology
970130
M9715787

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .